The company will provide the services for the VA's Million Veteran Program, which is studying the link between genes and disease in US veteran volunteers.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
At the Precision Medicine World Conference this week, researchers discussed how they plan to return genomic results to participants of research-focused sequencing studies.
The Milwaukee Journal Sentinel writes that veterans are signing up for the Million Veteran Program.
The contract was awarded as part of the VA's Precision Oncology Program, which aims to provide advanced clinical care and generate cancer biomarker data.
The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.
The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.
The test analyzes clinically relevant genetic variants for 14 genes related to certain pain and mental health medication responses to help guide clinicians' prescribing decisions.
Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.
In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.